CELİL ALEMDAR
Ulus Medical Journal - 2023;1(3):66-73
The current article’s goal is to examine the body of research on the use of bone marrowderived mesenchymal stem cell treatment to treat musculoskeletal disorders and to highlight the urgent need for more carefully planned clinical trials. Mesenchymal stem cells generated from bone marrow have garnered significant attention in the treatment of musculoskeletal disorders and injuries in recent years. The clinical application of BM-MSCs and other stem cell therapies has progressed well beyond the basic and translational research data needed to clarify the possible effectiveness of this orthobiologic therapeutic strategy. Mesenchymal stem cell therapy derived from bone marrow has shown promise in treating knee osteoarthritis, focal chondral lesions, shoulder pathologies such as glenohumeral arthritis, rotator cuff tears, and degenerative disk disease in the spine. These findings are consistent with early research findings. The majority of research that has been published to date are brief case series that frequently don’t have a control group or a set course of therapy. Mesenchymal stem cell therapy produced from bone marrow is becoming a more popular treatment for diseases and accidents related to the musculoskeletal system. Despite encouraging results from early clinical trials, methodological errors and a lack of trial standardization have restricted the inferences that can be made from the body of current research. The effectiveness and usefulness of BM-MSCs as a therapy option for different orthopedic disorders will become clearer with a deeper comprehension of the underlying mechanism of action and more meticulously planned clinical trials..
